HER2 has become one of the most successful therapeutic target for the treatment of various malignant tumors, including breast cancer, gastric cancer, esophageal cancer, head and neck tumors and urothelial cancer, etc. ADC have recently become one of the most popular research fields for anti-tumor agents, thereby representing the development direction of personalized precision therapy. This evidence concerns the gene ERBB2 and breast cancer.